587 results match your criteria Lupus Erythematosus Bullous


Drug-induced Bullous Pemphigoid and Lupus Erythematosus Occurring under Anti-TNF-α and IL-6 Therapy in a Patient with Rheumatoid Arthritis.

Intern Med 2020 Jul 7. Epub 2020 Jul 7.

Department of Rheumatology and Allergy, IMSUT Hospital, Institute of Medical Science, The University of Tokyo, Japan.

A 65-year-old Japanese woman, who was diagnosed with rheumatoid arthritis and Sjögren's syndrome with various autoantibodies including anti-DNA antibody, developed bullous pemphigoid and hematological abnormalities like lupus erythematosus after adalimumab therapy. The discontinuation of adalimumab resolved those disorders but polyarthritis thereafter relapsed. The introduction of abatacept was not effective, but tocilizumab was found to be effective for polyarthritis, however, thereafter both bullous disease and severe pancytopenia developed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2169/internalmedicine.4646-20DOI Listing

Juvenile bullous systemic lupus erythematosus - case report.

Acta Reumatol Port 2020 Jan-Mar;45(1):74-75

Hospital Garcia de Orta.

Bullous systemic lupus erythematosus (BSLE) is a rare autoimmune subepidermal blistering disease, with few cases described in childhood. We report a case of bullous systemic lupus erythematosus refractory to corticosteroid therapy in a 16-year-old female who was successfully treated with low dose dapsone. We highlight the rarity and the relevance of skin biopsy for a correct diagnosis of BSLE. Read More

View Article

Download full-text PDF

Source

Scarring alopecia in chronic cutaneous lupus erythematosus with neutrophils: A new scenario with therapeutic connotations.

J Cutan Pathol 2020 Jun 1. Epub 2020 Jun 1.

Department of Dermatology, Complexo Hospitalario Universitario de Ourense, Ourense, Spain.

The relationship between autoinflammatory and autoimmune conditions has been demonstrated in recent decades. Several autoimmune conditions exhibit an autoinflammatory component, which can manifest in various ways. Neutrophilic dermatosis in the context of lupus erythematosus (LE) is one example. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cup.13764DOI Listing

Simultaneous Bullous Pemphigoid and Vitiligo Associated with Adalimumab Therapy in a Patient with Psoriasis Vulgaris.

Indian Dermatol Online J 2020 Mar-Apr;11(2):229-231. Epub 2020 Mar 9.

Department of Dermatology, Hospital General de México, Ciudad de México, CDMX, Mexico.

Antitumor necrosis factors (TNFs) agents are increasingly being used for the effective treatment of diverse diseases. Due to its extensive use and longer duartion of treatment, there are a growing number of reports of the development of autoimmune conditions such as systemic lupus erythematosus, bullous pemphigoid (BP), and vitiligo associated with the use of anti-TNF agents. We describe a patient who developed BP as well as vitiligo after receiving treatment with adalimumab for plaque psoriasis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/idoj.IDOJ_53_19DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7247621PMC

Association between major depressive disorder and subsequent autoimmune skin diseases: A nationwide population-based cohort study.

J Affect Disord 2020 May 25;274:334-338. Epub 2020 May 25.

School of Medicine, National Yang-Ming University, Taipei, Taiwan; Department of Psychiatry, Taipei Veterans General Hospital, Taipei, Taiwan. Electronic address:

Background: Major depressive disorder (MDD) has been implicated as a risk factor for various immune-related disorders; however, the association between MDD and subsequent autoimmune skin diseases (ASDs) remains unclear. This study aimed to investigate the association of MDD with risk of subsequent ASDs.

Methods: Subjects were recruited from the National Health Insurance Research Database in Taiwan. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jad.2020.05.070DOI Listing
May 2020
3.383 Impact Factor

A case of bullous systemic lupus erythematosus presenting both IgG and IgA autoantibodies for collagen VII.

Int J Dermatol 2020 Jul 19;59(7):e260-e262. Epub 2020 May 19.

Department of Dermatology, Dokkyo Medical University School of Medicine, Mibu, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ijd.14940DOI Listing

Non-bullous neutrophilic lupus erythematosus-Muted bullous disease?

Indian J Pathol Microbiol 2020 Apr-Jun;63(2):305-308

Department of Pathology, ABVIMS and Dr. RML Hospital, New Delhi, India.

Non-bullous neutrophilic lupus erythematosus is a rare form of cutaneous lupus erythematosus (LE). We hereby present a case of 24-year-old female, known case of discoid LE (DLE) with negative ANA stabilized on hydroxychloroquine for 2 years. She reported new occurrence of erythematous, mildly pruritic, papular lesions and painful mucosal ulceration. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/IJPM.IJPM_704_19DOI Listing

[A case of bullous systemic lupus erythematosus with sloughing esophagitis].

Nihon Shokakibyo Gakkai Zasshi 2020 ;117(3):252-260

Department of Gastroenterology, Sanda City Hospital.

A 57-year-old female presented with a chief complaint of odynophagia during medical treatment for systemic lupus erythematosus (SLE). Endoscopy revealed sloughed mucosa along the entire esophageal length, and normal mucosa was easily stripped by withdrawal of the biopsy forceps. Blistering eruptions subsequently appeared on her upper extremities, trunk, and oral cavity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.11405/nisshoshi.117.252DOI Listing

Treatment of cutaneous lupus erythematosus: current approaches and future strategies.

Curr Opin Rheumatol 2020 May;32(3):208-214

Division of Rheumatology, Department of Internal Medicine.

Purpose Of Review: Cutaneous lupus erythematosus (CLE) is a highly heterogeneous autoimmune disease. No specific Federal Drug Administration-approved therapies for CLE-alone are available, and resistance to conventional treatments is common. This review will summarize current treatment approaches and pending treatment strategies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/BOR.0000000000000704DOI Listing

Off-label dermatologic uses of IL-17 inhibitors.

J Dermatolog Treat 2020 Mar 9:1-7. Epub 2020 Mar 9.

Department of Dermatology, Loma Linda University, Loma Linda, CA, USA.

IL-17 inhibitors, including secukinumab, brodalumab, and ixekizumab, have been U.S. Food and Drug Administration (FDA) approved for the treatment of psoriasis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/09546634.2020.1737638DOI Listing

Vitamin D in autoimmune bullous disease.

Authors:
Stefan Tukaj

Acta Biochim Pol 2020 Feb;67(1):1-5

Department of Molecular Biology, University of Gdańsk, Gdańsk, Poland.

Numerous epidemiological studies have suggested a link between vitamin D deficiency and the development of various autoimmune diseases, including diabetes mellitus type 1, rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis or systemic lupus erythematosus. More recently, such a link has been also proposed for autoimmune bullous diseases (AIBD). This is a relatively rare and potentially life-threatening, organ-specific group of inflammatory skin diseases characterized by the presence of tissue-bound and circulating autoantibodies against various molecules present in desmosomes (in pemphigus diseases) or hemidesmosomes (in pemphigoid diseases). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18388/abp.2020_2905DOI Listing
February 2020

Immune-mediated Skin Disorders and their Oral Manifestations in the Omani Population: A Hospital-based Study.

Oman Med J 2020 Jan 6;35(1):e84. Epub 2020 Jan 6.

Oral Basic Sciences, Oman Dental College, Muscat, Oman.

Objectives: We sought to determine the prevalence of immune-mediated skin disorders (IMDs), their oral manifestations, and the related comorbidity among Omani patients with IMDs attending the outpatient Department of Dermatology and Dental Clinic at Al Nahdha Hospital, Muscat.

Methods: We conducted a retrospective study of 236 newly-diagnosed patients with IMDs who attended the outpatient clinic between September 2014 and September 2017. Data, such as age, sex, investigations, diagnosis, comorbidity, and associated oral manifestations of the affected individuals, were collected from the hospital health information system. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5001/omj.2020.02DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6976739PMC
January 2020

Clinicopathological and Immunological Profile of Patients with Cutaneous Manifestations and their Relationship with Organ Involvement in Systemic Lupus Erythematosus Attending a Tertiary Care Center of Eastern India.

Indian J Dermatol 2020 Jan-Feb;65(1):22-28

Department of Dermatology, Calcutta National Medical College, Kolkata, West Bengal, India.

Background: Lupus erythematosus (LE) is an autoimmune disorder with diverse clinical manifestations ranging from mild cutaneous disorder to life-threatening systemic illness and associated with varying immunological parameters.

Aim: We conducted a study in a tertiary care center of eastern India to determine the clinical pattern, immunological profile of patients with cutaneous manifestations of systemic LE (SLE) and their relationship with organ involvement.

Materials And Methods: Fifty-five consecutive patients attending dermatology OPD having features consistent with cutaneous LE and fulfilling the criteria of SLE were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/ijd.IJD_282_19DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6986128PMC
February 2020

Association of herpes zoster and chronic inflammatory skin disease in US inpatients.

J Am Acad Dermatol 2020 Jan 17. Epub 2020 Jan 17.

Department of Dermatology, The George Washington University School of Medicine and Health Sciences, Washington, DC. Electronic address:

Background: Patients with chronic inflammatory skin disease (CISD) have potential risk factors for herpes zoster (HZ). However, little is known about HZ risk in CISD.

Objective: To determine whether CISD is associated with HZ. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2019.12.073DOI Listing
January 2020

Role of the Complement Pathway in Inflammatory Skin Diseases: A Focus on Hidradenitis Suppurativa.

J Invest Dermatol 2020 Mar 20;140(3):531-536.e1. Epub 2019 Dec 20.

Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Division of Dermatology, Department of Medicine, Women's College Hospital, Toronto, Ontario, Canada. Electronic address:

Although the role of immune dysregulation in hidradenitis suppurativa (HS) has yet to be elucidated, recent studies identified several complement abnormalities in patients with HS. The complement system serves a critical role in the modulation of immune response and regulation of cutaneous commensal bacteria. Complement is implicated in several inflammatory skin diseases including systemic lupus erythematosus, angioedema, pemphigus, bullous pemphigoid, and HS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jid.2019.09.009DOI Listing
March 2020
7.216 Impact Factor

Brief Update on Dermatologic Uses of Methotrexate

Skin Therapy Lett 2019 Nov;24(6):5-8

Department of Dermatology, McGovern Medical School, The University of Texas Health Sciences Center, Houston, TX, USA

Methotrexate (MTX), an agent originally intended for anti-neoplastic use, has been successfully employed in the treatment of a variety of dermatologic conditions. In addition to its multiple clinical indications, variable dosing and modes of administration make it a viable option for patients of all ages and most comorbidities. MTX is a folate analog that antagonizes dihydrofolate reductase, thus inhibiting thymidylate synthesis and, ultimately, the production of pyrimidine. Read More

View Article

Download full-text PDF

Source
November 2019
5 Reads

Coexistence of Autoimmune Encephalitis and Other Systemic Autoimmune Diseases.

Front Neurol 2019 31;10:1142. Epub 2019 Oct 31.

Department of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.

In recent years, the phenomenon of coexisting systemic autoimmune diseases (ADs) in patients with autoimmune encephalitis (AE) has been increasingly found, while its clinical significance remains unexplored. This study aimed to investigate the types and potential clinical associations of autoimmune comorbidities in patients with antibody-positive AE. A retrospective cohort study of patients with antibody-positive AE was conducted from 2011 to 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fneur.2019.01142DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6834766PMC
October 2019

Toxic epidermal necrolysis-like subacute cutaneous lupus erythematosus associated with lung carcinoma.

BMJ Case Rep 2019 Oct 13;12(10). Epub 2019 Oct 13.

Department of Dermatology, Hospital and University Centre of Coimbra, Coimbra, Portugal.

Specific vesiculobullous skin lesions in lupus erythematosus (LE) are rare and must be differentiated from toxic epidermal necrolysis (TEN), TEN-like dermatoses and other vesiculobullous conditions. We report a patient with typical subacute cutaneous lupus erythematous that progressed with large sheet-like areas of epidermal detachment and Nikolsky sign resembling TEN. She had a serological profile suggestive of underlying connective tissue disease, histological findings of interface dermatitis with a lymphocytic infiltrate, positive direct immunofluorescence, resolution with immunomodulation and lack of a culprit drug, features observed in TEN-like cutaneous lupus erythematous. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bcr-2019-231152DOI Listing
October 2019
2 Reads

[Immunohistochemical analysis for C3d, C4d, IgG, IgG4, and CD123 in diagnosis of autoimmune skin diseases].

Zhong Nan Da Xue Xue Bao Yi Xue Ban 2019 Aug;44(8):878-884

Department of Dermatology, Second Xiangya Hospital, Central South University, Changsha 410011, China.

Objective: To assess the value of immunohistochemical analysis for expressions of C3d, C4d, IgG, IgG4, and CD123 in the diagnosis of autoimmune skin diseases.
 Methods: We investigated the expressions of C3d, C4d, IgG, IgG4, and CD123 in paraffin-embedded, formalin-fixed tissues from 27 lupus erythematosus cases, including 8 discoid lupus erythematosus (DLE) cases, 4 subacute cutaneous lupus erythematosus (SCLE) cases, and 15 systemic lupus erythematosus (SLE) cases. Tissues from 15 dermatomyositis (DM) cases, 15 bullous pemphigoid (BP) cases, and 15 pemphigus cases were examined by immunohistochemical analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.11817/j.issn.1672-7347.2019.180800DOI Listing
August 2019
2 Reads

Vesiculobullous diseases in relation to lupus erythematosus.

Clin Cosmet Investig Dermatol 2019 4;12:653-667. Epub 2019 Sep 4.

Division of Dermatology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

Vesiculobullous lesions in lupus erythematosus (LE) are a rare cutaneous manifestation of cutaneous and/or systemic LE with variable presentation. While the minor forms of LE-associated vesiculobullous disease may cause disfigurement and discomfort, the severe forms can present with hyperacute reaction and life-threatening consequences. Specific LE and aspecific cutaneous LE are defined by the presence or absence of interface change on histopathology that can be applied to vesiculobullous diseases in relation to LE. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CCID.S220906DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6732903PMC
September 2019
3 Reads

Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders.

Front Immunol 2019 6;10:1990. Epub 2019 Sep 6.

Department of Immunology, University Hospital Zurich, Zurich, Switzerland.

During the past years biologic agents (also termed biologicals or biologics) have become a crucial treatment option in immunological diseases. Numerous articles have been published on biologicals, which complicates the decision making process on the use of the most appropriate biologic for a given immune-mediated disease. This systematic review is the first of a series of articles assessing the safety and efficacy of B cell-targeting biologics for the treatment of immune-mediated diseases. Read More

View Article

Download full-text PDF

Source
https://www.frontiersin.org/article/10.3389/fimmu.2019.01990
Publisher Site
http://dx.doi.org/10.3389/fimmu.2019.01990DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6743223PMC
September 2019
6 Reads

Neutrophilic dermatoses as adverse effects of checkpoint inhibitors: A review.

Dermatol Ther 2019 09 4;32(5):e13074. Epub 2019 Sep 4.

Department of Dermatology, Keck School of Medicine at the University of Southern California, Los Angeles, California.

Checkpoint inhibitors are a new class of drugs that enhance the immune system's intrinsic ability to destroy tumor cells by blocking signaling through the programmed cell death (PD-1) receptor, its ligand (PD-L1), and the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). The resulting increase in immunologic activity is responsible for a variety of adverse cutaneous reactions, which sometimes include neutrophilic dermatoses. We queried the PubMed database for existing cases of checkpoint inhibitors causing neutrophilic dermatoses. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1111/dth.13074
Publisher Site
http://dx.doi.org/10.1111/dth.13074DOI Listing
September 2019
4 Reads

[Bullous systemic lupus erythematosus complicated by lupus nephritis in a 12-year-old girl].

Zhongguo Dang Dai Er Ke Za Zhi 2019 08;21(8):836-838

Department of Pediatrics, Xiangya Hospital, Central South University, Changsha 410008, China.

View Article

Download full-text PDF

Source
August 2019
3 Reads

Efficacy of methotrexate as anti-inflammatory and anti-proliferative drug in dermatology: Three case reports.

Exp Ther Med 2019 Aug 19;18(2):905-910. Epub 2019 Apr 19.

Faculty of Medicine, 'Carol Davila' University of Medicine and Pharmacy, 050474 Bucharest, Romania.

Methotrexate (MTX) is a folic acid analog with anti-proliferative (anti-neoplastic, cytotoxic), immunosuppressive and anti-inflammatory properties, which has been used in the treatment of various cutaneous disorders, such as psoriasis, keratoacanthoma, pityriasis rubra pilaris, atopic dermatitis, mycosis fungoides, bullous skin diseases, systemic sclerosis, morphea, lupus erythematosus, dermatomyositis and crusted scabies. Inhibition of cell proliferation is explained through its role in blocking DNA/RNA synthesis, by inhibiting dihydrofolate reductase, necessary for the production of pyrimidine and purine nucleotides. An anticancer effect can be related to α-oxoaldehyde metabolism (MTX increases methylglyoxal levels). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/etm.2019.7511DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6639959PMC
August 2019
12 Reads

Bullous systemic lupus erythematosus successfully treated with rituximab.

Cutis 2019 Jun;103(6):E5-E7

Section of Dermatology, Walter Reed National Military Medical Center, Bethesda, Maryland; and Department of Dermatology, Uniformed Services University of the Health Sciences, Bethesda, USA.

Bullous systemic lupus erythematosus (BSLE) is a rare complication of systemic lupus erythematosus (SLE) characterized by cutaneous vesicles and bullae with a primarily neutrophilic infiltrate on histopathology. Bullous SLE is a heterogeneous disease without pathognomonic clinical features, making the diagnosis and differentiation from other blistering diseases challenging. We present the case of a single patient with SLE in whom 3 different clinical appearances of BSLE manifested over 5 years. Read More

View Article

Download full-text PDF

Source
June 2019
5 Reads

High-Dose Intravenous Immunoglobulin in Skin Autoimmune Disease.

Front Immunol 2019 11;10:1090. Epub 2019 Jun 11.

Department of Dermatology, University of Heidelberg, Heidelberg, Germany.

The immunomodulatory potential and low incidence of severe side effects of high-dose intravenous immunoglobulin (IVIg) treatment led to its successful application in a variety of dermatological autoimmune diseases over the last two decades. IVIg is usually administered at a dose of 2 g per kg body weight distributed over 2-5 days every 4 weeks. They are most commonly used as a second- or third-line treatment in dermatological autoimmune disease (pemphigus vulgaris, pemphigus foliaceus, bullous pemphigoid, mucous membrane pemphigoid, epidermolysis bullosa acquisita, dermatomyositis, systemic vasculitis, and systemic lupus erythematosus). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2019.01090DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6579842PMC
June 2019
10 Reads

Bullous Lupus Under Nivolumab Treatment for Lung Cancer: A Case Report With Systematic Literature Review.

Anticancer Res 2019 Jun;39(6):3003-3008

Internal Medicine Department, Jules Bordet Institute, Free University of Brussels (ULB), Brussels, Belgium.

Background: Various immune-related adverse events (irAEs) have been reported to be associated with the use of immune checkpoint inhibitors. We report a case of a patient with lung cancer treated with nivolumab who developed a bullous eruption and give a systematic review of the literature on irAEs in patients treated with immune checkpoint inhibitors for lung cancer.

Case Report: A patient with lung adenocarcinoma developed a non-specific skin lesion at the time of his cancer diagnosis followed by flare episodes until the eighth cycle of nivolumab, when he developed a bullous lupus. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.13432DOI Listing
June 2019
9 Reads

Bullous systemic lupus erythematosus - a case report.

Autops Case Rep 2019 Jan-Mar;9(1):e2018069. Epub 2019 Feb 25.

Universidade de São Paulo, Hospital Universitário, Department of Internal Medcine. São Paulo, SP, Brazil.

Skin involvement in systemic lupus erythematosus (SLE) occurs in more than 75% of patients with this condition. Vesicles and blisters in lupus erythematosus (LE) may be present in SLE secondary to interface vacuolar changes in the epidermis, in discoid LE also secondary to vacuolar epidermal changes, and in bullous LE secondary to antibodies anti-collagen VII deposits with neutrophilic aggregates. In addition, blisters can occur due to the association of SLE with other autoimmune blistering diseases (e. Read More

View Article

Download full-text PDF

Source
http://www.autopsyandcasereports.org/article/doi/10.4322/acr
Publisher Site
http://dx.doi.org/10.4322/acr.2018.069DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394362PMC
February 2019
26 Reads

Bullous lupus erythematosus with an erythema gyratum repens-like pattern.

Dermatol Online J 2019 Jan 15;25(1). Epub 2019 Jan 15.

Department of Dermatology, Centro Hospitalar Vila Nova de Gaia/Espinho, Vila Nova de Gaia.

Bullous lupus erythematosus is a rare clinical form of lupus. The diagnosis is challenging and involves the exclusion of other subepidermal bullous dermatoses. We present a 21-year-old woman with erythematosus, polycyclic plaques with vesiculobullae along the periphery, creating an erythema gyratum repens-like pattern on acral regions. Read More

View Article

Download full-text PDF

Source
January 2019
14 Reads

Systemic Lupus Erythematosus with Linear IgA Bullous Dermatosis and Renal Vascular Lesions: An Extremely Rare Association.

Indian J Nephrol 2018 Nov-Dec;28(6):465-467

Department of Pathology, St. John's Medical College, Bengaluru, Karnataka, India.

We report a rare case of systemic lupus erythematosus presenting initially with cutaneous manifestations of linear IgA bullous dermatosis. Later the patient developed renal abnormalities due to thrombotic microangiopathy and lupus nephritis with inflammatory necrotizing vasculitis. Paucity of immune deposits was observed on Immunofluorescence. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/ijn.IJN_200_17DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6309391PMC
January 2019
7 Reads

Terbinafine-Induced Relapse of Bullous Lupus Erythematosus.

J Clin Rheumatol 2018 Dec 28. Epub 2018 Dec 28.

University of Virginia School of Medicine Charlottesville, VA Department of Dermatology University of Virginia Health System Charlottesville, VA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RHU.0000000000000945DOI Listing
December 2018
5 Reads

Seizures as a clinical manifestation in somatic autoimmune disorders.

Seizure 2019 Jan 5;64:59-64. Epub 2018 Dec 5.

Stichting Epilepsie Instellingen Nederland (SEIN), Achterweg 5, Heemstede, 2103SW, Netherlands; NIHR University College London Hospitals Biomedical Research Centre, UCL Queen Square Institute of Neurology, London, WC1N 3BG, United Kingdom; Chalfont Centre for Epilepsy, Chalfont St Peter, Bucks, SL9 0RJ, United Kingdom.

The risk of epileptic seizures seems increased in several systemic autoimmune disorders including systemic lupus erythematosus, type 1 diabetes mellitus, myasthenia gravis, celiac disease, rheumatoid arthritis, Hashimoto's encephalopathy, psoriasis, multiple sclerosis, neuromyelitis optica, and bullous pemphigoid. Immune dysfunction may be partly responsible for this association. Elevated levels of pro-inflammatory cytokines, autoantibodies seen in these autoimmune disorders and antibodies against neuronal antigens may contribute to the etiopathogenesis of seizures and epilepsy associated to immune conditions. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10591311183058
Publisher Site
http://dx.doi.org/10.1016/j.seizure.2018.11.012DOI Listing
January 2019
141 Reads
2.800 Impact Factor

Exosomes in chronic inflammatory skin diseases and skin tumors.

Exp Dermatol 2019 03;28(3):213-218

Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Exosomes are membrane vesicles of endocytic origin that can mediate communication between cells and the transport of cellular components such as microRNAs, mRNAs, proteins and DNA. Recently, exosomes have been under investigation for their significant roles in both healthy physiology and disease states. Herein, we review the role of exosomes in chronic inflammatory skin diseases and skin tumors, especially focusing on systemic lupus erythematosus, psoriasis, atopic dermatitis, bullous pemphigoid and melanoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/exd.13857DOI Listing
March 2019
9 Reads

Does Complement Have a Role in the Pathogenesis of Alopecia Areata?

Skin Appendage Disord 2018 Oct 22;4(4):261-263. Epub 2018 Mar 22.

Department of Dermatology, University of California, Irvine, Irvine, California, USA.

Alopecia areata (AA) is an autoimmune disorder in which immune attack of the anagen follicle causes hair loss in approximately 2% of the population. Although the pathogenesis of AA has not been fully determined, most likely it is mediated by a variety of factors including cellular/humoral immunity and genetic predisposition. Researchers have been interested in the possible role of the complement pathway in AA since the 1970s. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000487448DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219235PMC
October 2018
37 Reads

[When drugs induce cutaneous lupus erythematosus].

Ugeskr Laeger 2018 Oct;180(41)

Drug-induced subacute cutaneous lupus erythematosus (DI-SCLE) is defined as an adverse reaction to continuous use of a culprit drug. The reaction resolves upon drug withdrawal. More than 50 drugs have been linked to DI-SCLE, and it is estimated, that around 20% of the SCLE cases are drug-induced. Read More

View Article

Download full-text PDF

Source
October 2018
14 Reads

Scleredema of Buschke associated with lichen sclerosus: Three cases.

Indian J Dermatol Venereol Leprol 2020 May-Jun;86(3):272-277

"Mario Aresu" Department of Medical Science, Section of Dermatology, University of Cagliari, Cagliari, Italy.

Scleredema adultorum of Buschke is a rare fibromucinous, scleroderma-like connective tissue disease most commonly found in a post-infectious setting or linked to hematological disorders or diabetes. Lichen sclerosus et atrophicus is an autoimmune condition only in 2.5% of cases localized exclusively at an extragenital site, occurring in up to 34% of patients in association with other autoimmune diseases such as vitiligo, thyroid disorders, alopecia areata, lichen planus, morphea, pernicious anemia and systemic lupus erythematosus. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/ijdvl.IJDVL_288_17DOI Listing
October 2018
23 Reads

Bullous systemic lupus erythematosus associated with increased activity of lupus nephritis: a case report and review of the literature.

Postepy Dermatol Alergol 2018 Aug 21;35(4):431-433. Epub 2018 Aug 21.

Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wroclaw, Poland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5114/ada.2018.77676DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6130133PMC
August 2018
8 Reads

Autoimmune skin disease among dermatology outpatients in Botswana: a retrospective review.

Int J Dermatol 2019 Jan 31;58(1):50-53. Epub 2018 Aug 31.

Department of Dermatology, University of Iowa Carver College of Medicine, Iowa City, IA, USA.

Background: There is a paucity of data describing autoimmune skin diseases in sub-Saharan Africa and in HIV positive cohorts. We describe the incidence of autoimmune skin diseases in public dermatology clinics in Botswana.

Methods: New patient records from public dermatology clinics were reviewed retrospectively for the period of September 2008 to December 2015. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ijd.14201DOI Listing
January 2019
51 Reads
1.230 Impact Factor

Fogo selvagem: endemic pemphigus foliaceus.

An Bras Dermatol 2018 Sep-Oct;93(5):638-650

Dermatology Service, Hospital Maria Aparecida Pedrossian, Universidade Federal de Mato Grosso do Sul, Campo Grande (MS), Brazil.

Fogo selvagem or endemic pemphigus foliaceus is an autoimmune acantholytic anti-cadherin bullous disease that primarily affects seborrheic areas, which might disseminate. Brazil has the world's largest number of patients, mainly in the Central-West region, but the disease has also been reported in other South American countries. It affects young people and adults who have been exposed to rural areas, with occurrence of familial cases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1590/abd1806-4841.20188235DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6106655PMC
October 2018
45 Reads

Toxic epidermal necrolysis-like acute cutaneous lupus erythematosus: report of a case and review of the literature.

Dermatol Online J 2018 05 15;24(5). Epub 2018 May 15.

Department of Dermatology, University of California San Diego, La Jolla, California.

Severe bullous eruptions in systemic lupus erythematosus (SLE) patients include bullous SLE, Rowell syndrome, toxic epidermal necrolysis (TEN), and TEN-like eruption of acute cutaneous lupus (TEN-like ACLE). TEN-like ACLE, a rare manifestation of SLE that closely mimics TEN, can be distinguished by characteristic clinical and laboratory findings. A 27-year-old man with SLE who developed TEN-like ACLE after initiating mycophenolate mofetil for active SLE is reported. Read More

View Article

Download full-text PDF

Source
May 2018
49 Reads

The Value of Type IV Collagen Immunohistochemical Staining in the Differential Diagnosis of Autoimmune Subepidermal Bullous Diseases.

Acta Dermatovenerol Croat 2018 Jun;26(2):133-138

Hai-Jin Park, MD, Inje Univ. Ilsan Paik Hospital, 170 Juwha-Ro, Ilsanseo-gu, Goyang, Gyeonggi-do, Korea;

Autoimmune subepidermal bullous diseases (AISBDs) exhibit various clinical presentations, histological appearances, prognoses, and responses to treatment. Many diagnostic techniques, such as direct immunofluorescence (IF), indirect salt-split skin IF, and enzyme-linked immunosorbent assays, are used in the differential diagnoses of AISBDs. However, these techniques require fresh frozen tissue, expensive laboratory equipment, and sophisticated laboratory techniques. Read More

View Article

Download full-text PDF

Source
June 2018
15 Reads

Bullous Pemphigoid Associated with Adalimumab Therapy in a Patient with Ulcerative Colitis.

Case Rep Dermatol 2018 May-Aug;10(2):145-148. Epub 2018 May 24.

Department of Dermatology, University Medical Center Regensburg, Regensburg, Germany.

Bullous pemphigoid (BP) is a blistering autoimmune disease mainly observed in elderly patients. Several triggers are known for this autoimmune disease and some drugs are known to be a cause of BP. However, there are only few case reports on the induction of BP under adalimumab therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000489163DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6006603PMC
May 2018
8 Reads

Clindamycin-induced Maculopapular Exanthema with Preferential Involvement of Striae Distensae: A Koebner phenomenon?

Acta Dermatovenerol Croat 2018 Apr;26(1):61-63

Benigno Monteagudo-Sánchez, MD, Hospital Arquitecto Marcide, Avenida Residencia SN , 15405 Ferrol (A Coruńa), A Coruńa, Spain;

Clindamycin is a lincomycin-derived antibiotic useful for the treatment of anaerobic and Gram-positive aerobic bacterial infections. Cutaneous adverse reactions are usually maculopapular exanthemas, although hypersensitivity syndrome, acute generalized exanthematous pustulosis, and Stevens-Johnson syndrome have also been reported (1). We report the case of a patient with a maculopapular rash triggered by clindamycin who developed cutaneous lesions on striae distensae (SD). Read More

View Article

Download full-text PDF

Source
April 2018
56 Reads

Complement Activation in Inflammatory Skin Diseases.

Front Immunol 2018 16;9:639. Epub 2018 Apr 16.

Department of Pathology, Erasmus Medical Center Rotterdam, Rotterdam, Netherlands.

The complement system is a fundamental part of the innate immune system, playing a crucial role in host defense against various pathogens, such as bacteria, viruses, and fungi. Activation of complement results in production of several molecules mediating chemotaxis, opsonization, and mast cell degranulation, which can contribute to the elimination of pathogenic organisms and inflammation. Furthermore, the complement system also has regulating properties in inflammatory and immune responses. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2018.00639DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5911619PMC
June 2019
33 Reads

Immunoglobulin E-Mediated Autoimmunity.

Front Immunol 2018 9;9:689. Epub 2018 Apr 9.

Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany.

The study of autoimmunity mediated by immunoglobulin E (IgE) autoantibodies, which may be termed autoallergy, is in its infancy. It is now recognized that systemic lupus erythematosus, bullous pemphigoid (BP), and chronic urticaria, both spontaneous and inducible, are most likely to be mediated, at least in part, by IgE autoantibodies. The situation in other conditions, such as autoimmune uveitis, rheumatoid arthritis, hyperthyroid Graves' disease, autoimmune pancreatitis, and even asthma, is far less clear but evidence for autoallergy is accumulating. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2018.00689DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5900004PMC
June 2019
41 Reads

Leukocytoclastic Vasculitis Concurrent With Bullous Systemic Lupus Erythematosus Manifesting Striking Wood-Grain and Wi-Fi Sign-like Purpuric Lesions.

J Clin Rheumatol 2019 10;25(7):e104-e105

From the Department of Dermatology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RHU.0000000000000717DOI Listing
October 2019
9 Reads